Several reversible acetylcholine esterase inhibitors have been utilized to treat Alzheimer's disease and have been proposed as potential prophylactic therapeutic options for acetylcholinesterase toxicity caused by NA exposure given that they can occupy acetylcholinesterase binding sites, therefore minimizing the effects of NA. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.